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Plasma fibronectin purified from the plasma of metastatic breast cancer patients has been studied by light scattering. 
It clearly shows abnormal self-aggregation properties; the possible significance of these findings to the in vivo situation 
is discussed. 
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1. INTRODUCTION 
Fibronectins are a class of extracellular 
glycoproteins (520 kDa) (review [l]). Their 
primary structure can vary and depends on the 
alternative splicing of a unique gene which can 
generate at least ten different variants [2]. The 
molecules are composed of the concatenation of 
three types of homologous sequences [3] forming 
two similar, but not identical, chains linked near 
the carboxy-terminus end by two interchain 
disulphide bonds. One of the most striking 
features of the fibronectin molecules is that they 
are made of a succession of protease-resistant do- 
mains which can bind specifically to one or more 
of heparin, fibrin, factor VIIa, Clq, cell surface, 
DNA, gelatin collagen [l]. 
In solution, plasma fibronectin as studied by 
light scattering techniques does not show any 
significant self-aggregation properties [4], but 
fibronectins are present in the extracellular matrix 
in an insoluble, fibrillar, form [5]. 
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Receptors to fibronectin on the cell surface have 
been described [6] and a transmembranous con- 
tinuity between cytoskeleton and fibronectins 
through the receptor has been demonstrated [7]. 
The association of fibronectin with the matrix 
assembly receptor has also been reported [S]. The 
position of fibronectin in the cell attachment pro- 
cess is therefore very important and it is probable 
that fibronectins are likely to be the extracellular 
matrix protein in closest contact with cells. 
The involvement of fibronectin in cancer and 
metastatic processes has been investigated along 
three separate lines all related to early events of 
metastasis leading to the detachment of cells and 
their penetration into the blood stream: 
(i) Synthesis of specific fibronectins by altera- 
tions of the primary structure [9] and carbohydrate 
side chains composition [lo]. 
(ii) Modification at the cellular receptor level 
[l l] and deposition rates of fibronectin in the 
matrix [ 121. 
(iii) Degradation of fibronectin by tumour cells 
[ 131. Specific enzymes have been described [ 141. 
Surprisingly the role of fibronectins in the next 
stage, that is anchoring of the cell migrating in the 
blood stream, has been much less studied. De 
Petro et al. 1151 have shown that transformation 
enhancement activity in the plasma of tumour pa- 
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tients was linked with fibronectin. We report here 
evidence, from a light scattering study, that plasma 
fibronectin from breast metastatic ancer patients 
possesses significantly different hydrodynamic 
properties from normal plasma fibronectin. 
2. MATERIALS AND METHODS 
All affinity chromatography media were from Pharmacia 
(Sweden), and all other chemicals (analytical grade) were from 
BDH (England). 
2.1. Protein purification 
Blood samples were treated with 20% sodium citrate, 25 mM 
EDTA (1 vol. per 4 vols blood) and centrifuged at 200 x g for 
5 min in a bench centrifuge. The supernatant was removed and 
was either frozen at -20°C or processed immediately as 
follows. 
To remove any precipitates the plasma was centrifuged at 
10000 x g for 1 h and then chromatographed on a 2 cm2 x 
1 cm gelatin-Sepharose column as described [16]. The sample 
was eluted with 4 M urea, 50 mM Tris-HCl (pH 7.4) but in 
order to test its possible influence on aggregation, 1M arginine, 
50 mM Tris-HCl (pH 7.4) was also used for one sample with no 
detectable difference. Exhaustive dialysis in 50 mM Tris-HCl, 
100 mM NaCl, pH 7.4 (dialysis buffer), was then performed to 
remove any urea traces. 
To eliminate any possible artefactual contamination two 
samples were rechromatographed on a heparin-Sepharose col- 
umn rinsed by dialysis buffer and then eluted by 1 M NaCl, 
50 mM Tris-HCl, 1 mM EDTA (pH 7.4) and redialysed in 
dialysis buffer. 
PMSF (0.05 mM) was present in all buffers and EDTA 
(5 mM) was added to all buffers used for purification. All 
specimens were examined by 5 or 6% discontinuous PAGE gels 
according to Laemmli [17]. 
2.2. Photon correlation spectroscopy 
All work presented here was performed on a type 4700~ 
Malvern system (Malvern Instruments, England). The argon- 
ion laser (Innova 4, USA) was used at 514.5 nm with a power 
of approx. 150 mW. 
For measurements on the fibronectin molecule the ex- 
perimental time was set between 5 and 15 s with no noticeable 
difference between results. Each measurement involved the ac- 
cumulation of a number of runs; the software calculated the 
mean value of total counts for each run and rejected any run 
with a significant difference in integrated counts. 
To remove any possible dust or contaminant from the 1 cm 
diameter quartz cells (ALV Lasers, FRG), they and their teflon 
caps were stored in pure sulphuric acid. Prior to use they were 
washed 20 times with double-distilled water to remove any 
traces of acid and three times further with filtered sample buffer 
to ensure that the buffer composition of the sample would not 
be altered by some remaining water. All buffers and all but one 
sample were filtered through 200 nm pore size Nucleopore 
filters (USA). These are well known for their highly constant 
pore size as well as low retention of the sample because of their 
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design as flat surfaces as opposed to ordinary filters which have 
mesh-like surfaces. 
To test the influence of filtration one sample was centrifuged 
and showed no difference in properties from filtered samples. 
When filtering the samples care was taken to avoid any distur- 
bance leading to aggregation. We avoided the use of metal 
needles which leads to metal contamination thereby triggering 
fibronectin polymerisation, as well as creating high-speed flows 
possibly leading to aggregation. 
The first-order correlation function was calculated from the 
measured second-order and related to the diffusion coefficient 
D and polydispersity index (review [18]). No correction was 
made for buffer viscosity which was assumed to be the same as 
pure water. The analysis by the software has a specific feature 
to estimate the diffusion coefficient distribution for 
polydisperse solutions. The software retains in the memory the 
shape of correlation functions for a large number of diffusion 
coefficients. It then calculates a multiexponential curve and fits 
it with the observed one. It is important o note that no assump- 
tion about the distribution of particles is made. 
2.3. Molecular mass determination by light scattering 
When the concentrations were high enough to produce per- 
missible signal-to-noise ratio, molecular mass estimations were 
made using the classical method of Zimm [19]. 
3. RESULTS 
Fig. 1 shows the diffusion coefficient/scattering 
intensity profile for normal plasma fibronectin 
(open squares) and for one sample of gelatin 
affinity-purified fibronectin from metastatic 
cancer patient plasma (black squares). 
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Fig. 1. Diffusion coefficient/scattering intensity profile of 
(U-U) normal plasma fibronectin and (m---m) one sample of 
gelatin-affinity purified fibronectin from plasma of metastatic 
cancer patient. 
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Table 1 
Sample Poly- Mole- 
disper- cular 
sity mass 
(o/o) &Da) 
(1) Samples purified by gelatin affinity only (4 samples): 
D population 1 D population 2 
(cm’/s) (cm’/s) 
0.29 f 0.07 x lo-’ 0.97 k 0.4 x IO-’ 55 4000 
(2) Samples repurified on heparin-Sepharose (2 samples): 
D population 1 D population 2 
(cm*/s) (cm*/s) 
1.12 f 0.2 x 10-7 2.80 f 0.3 x lo-’ 38 
(3) Normal plasma fibronectin: 
Monodisperse 
distribution 
D = 2.2 x lo-’ 
(cm*/s) 10 500 
4. DISCUSSION 
The most immediate result of our study is that 
plasma fibronectin prepared from metastatic 
cancer patients, when studied by dynamic light 
scattering, presents a polydisperse distribution, 
with two populations with markedly different dif- 
fusion coefficients. This contrasts with fibronectin 
purified from healthy individuals which presents a 
monodisperse distribution as shown in fig. 1 as well 
as in the literature 141. 
The analysis of the measured diffusion coeffi- 
cients shows that: (1) Fibronectin from metastatic 
cancer patients which was purified solely on 
gelatin-Sepharose comprises two populations of 
material arger than normal plasma fibronectin. (2) 
Heparin-repurified samples comprise one popula- 
tion of larger objects and one population of slight- 
ly smaller objects. 
(i) Proof that the material scattering light is 
fibronectin: 
- The presence of protein contaminating the 
fibronectin preparation would be detected on the 
PAGE control gels. 
- If contaminating material had been present, it 
would have been removed by the combination of 
various preparation procedures: for example, if 
the contaminants were eluted by 4 M urea only and 
they would not appear with material eluted from 
the gelatin column by 1 M arginine or repurified 
on the immobilised-heparin column, otherwise 
contaminants would have been eluted by high ionic 
strength, and therefore be eluted before fibronec- 
tin during the 1 M NaCl wash of the gelatin 
column. 
- Furthermore, fibronectin alone binds to gelatin 
at high salt concentration and heparin at 
physiological salt concentration. 
(ii) How much material is in an aggregated form? 
The intensity of light scattering is proportional 
to the square of the mass of the scattering particles 
and thus to the sixth power of their size; so, clearly 
to allow detection of the higher diffusion coeffi- 
cient values (i.e. those particles with smaller sizes) 
the high molecular mass material must represent a 
small number fraction of the total sample. 
(iii) Why does the high diffusion coefficient 
population of fibronectin from cancer patients 
have a translational diffusion coefficient value (0) 
different from that of normal plasma fibronectin? 
This is not too surprising, since the diffusion 
coefficients have to be calculated from a correla- 
tion function containing two decay rates, therefore 
the resolution is low. It is important to note that 
this is not a problem of noise but simply that the 
resolution is low when the distributions of two 
populations are close which means that the decays 
in the correlation function are not sufficiently 
dissimilar to estimate them precisely (the same 
problem occurs with Scatchard plots when two 
binding sites have similar dissociation constants). 
In addition, this loss in resolution is a direct conse- 
quence of the polydispersity and it lowers the 
quality of the diffusion coefficient measurements 
but the presence of aggregation is clearly estab- 
lished. This is confirmed by the very high values of 
the polydispersity index. 
(iv) The important point established by our 
measurements i the presence of a low D popula- 
tion (i.e. large aggregates) in plasma fibronectin 
purified from metastatic ancer patients. As shown 
above in point (i), identification with fibronectin is 
clear but it is more difficult to determine whether 
such aggregates exist in vivo: 
- They clearly exist at concentrations similar to 
the in vivo situation. 
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- The exclusion limit of the gelatin affinity col- 
umn (Sepharose 4B) is smaller than that of the 
heparin affinity column (Sepharose CL6b). 
Despite this fact a considerable reduction in the 
size of the aggregates occurs after heparin affinity 
repurification. This would suggest hat aggregates 
cannot easily dissociate after formation. 
- Because of their size they would be excluded 
from the gelatin column, being directly eluted in 
the first preparation step. So, the more likely 
hypothesis is that they form during the preparation 
where the use of urea or 1 M arginine buffer leads 
to unfolding of the protein. The presence of these 
large aggregates in vivo cannot be stated with cer- 
tainty. 
- They are not the consequence of filtration 
because one sample that had been centrifuged still 
presented abnormal aggregation. 
(v) We can only speculate on the origin of 
fibronectin presenting this abnormal aggregation 
property in vitro. 
The presence in the blood stream of fibronectin 
synthesised by tumour tissues seems unlikely 
because tumour cells have been shown to degrade 
fibronectin in tissues [ 131 and fibronectin pro- 
duced in tissues would have considerable difficulty 
migrating considering its binding properties. Fur- 
thermore, the amount produced would be very low 
compared to existing normal plasma fibronectin. 
Our conclusion is that the aggregates detected are 
genuine fibronectin with a different structure from 
that of normal plasma fibronectin. It could be pre- 
sent in plasma from confirmed metastatic cancer 
patients through modification in the blood of a 
small fraction of preexisting plasma fibronectin or 
could represent a form used by the metastatic ells 
to anchor at the surface of a blood capillary in 
their target organ. 
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